Clinical Trial Update: A Phase 2b Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Active Non-segmental Vitiligo Subjects [Phase 2]

View source ↗

Summary

Phase 2b study evaluating PF-06651600 and PF-06700841 in active non-segmental vitiligo has completed; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vitiligo

Drugs mentioned

• PF-06651600 (PF-06651600)
• PF-06700841

Snippet

Sponsor: Pfizer | Conditions: Active Non-segmental Vitiligo | Phase 2 | Status: COMPLETED | Results posted: 2022-03-25